
Director · LB PHARMACEUTICALS INC · LB PHARMACEUTICALS INC — Stock Option (Right to Buy)
Grant or award — administrative, little informational value
No reported dollar value · new position
Disclosed 2 business days after execution (deadline: 2)
First recorded trade by this actor in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Kozauer Susan GaniChief Medical Officer | Grant or award | A | — 200.0K sh | Oct 13, 2026 traded Oct 9, 2026 | |
| 9 | Miller Joseph MChief Financial Officer | Grant or award | A | — 200.0K sh | Oct 13, 2026 traded Oct 9, 2026 | |
| 9 | Luse RebeccaDirector | Grant or award | A | — 10.0K sh | Jun 5, 2026 traded Jun 3, 2026 | |
| 9 | Lenz Robert A.Director | Grant or award | A | — 20.0K sh | Mar 10, 2026 traded Mar 6, 2026 | |
| 9 | Pai Panandiker Kaya KamleshChief Commercial Officer | Grant or award | A | — 195.0K sh | Dec 11, 2025 traded Dec 10, 2025 |
Read directly from the primary public document; every field below is as reported by the filer.
Lenz Robert A. filed this Form 4 reporting a grant or award of LBRX on Jun 3, 2026. It became public on Jun 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.